Interleukin-6 (IL-6) is a multifunctional cytokine which is made by osteoblasts and has diverse effects on bone metabolism. We studied the interaction of IL-6 with the Ca2" and cAMP signaling systems in the osteoblastic cell line UMR-106 and in primary osteoblastic cultures derived from neonatal rat calvariae. IL-6 did not alter basal intracellular calcium concentration (ICa2+J1) but inhibited Ca2+ transients induced by parathyroid hormone (PTH), prostaglandin E2 (PGE2), and endothelin-1 in both dose-(100-400 U/ml) and time-(4-48 h) dependent manners. The effect of the cytokine was abolished by the tyrosine kinase inhibitor, herbimycin A (50 ng/ml). The IL-6 effect on the Ca2+ message system was related to suppressed production of hormonally induced inositol 1,4,5-triphosphate and inhibition of Ca2+ release from intracellular stores. Hormonally induced calcium entry pathways (estimated by using Mn2+ as a surrogate for Ca2+) were not, however, altered by the cytokine. IL-6 did not modulate cAMP generation in osteoblasts. With respect to osteoblast function, IL-6, although having no effect on cell proliferation by itself, greatly enhanced the antiproliferative effect of PGE2 and PTH. Because the production of IL-6 in osteoblasts is stimulated by calciotropic hormones (e.g., PIH and PGE2), the suppressive effect of the cytokine on hormonally induced Ca2+ transients may serve as an autocrine/paracrine mechanism for modulating the effect of hormones on bone metabolism. (J. Clin. Invest.
Introduction
IL-6 is a recently described multifunctional cytokine which mediates pleiotropic functions in various types of cells (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) . The biological functions of IL-6 are mediated through a specific receptor (IL-6R)' the cDNA of which has already been cloned (16) (17) (18) (19) (20) . The IL-6R system consists of a 80-kD ligand-binding domain and a 130-kD signal-transducing component (gp 130). Binding of IL-6 to its receptor triggers dimerization ofgp 130 which, in turn, activates intracellular tyrosine kinases (TKs) (20) (21) (22) .
This article focuses on the role that IL-6 plays in bone metabolism. The cytokine is produced in osteoblasts (23) and its production is regulated by a host offactors including PTH (24, 25) , IL-1, TNF, and 1,25 (OH )2D3 (26) (27) (28) . Although the role of IL-6 in the bone microenvironment is not fully elucidated, the majority ofevidence suggests that IL-6 possesses a bone-resorbing activity either by itself or in concert with other osteotropic agents (23) . This effect of the cytokine is ascribed primarily to increased formation of osteoclasts from hematopoietic progenitors (23, 25, 29) . Thus, organ cultures containing predominantly mature osteoclasts, do not manifest bone resorption in response to 31) . The role of IL-6 as an osteotropic agent in a clinical setting has been demonstrated in rheumatoid arthritis, where the cytokine mediates juxtaarticular bone resorption (32) , in the bone resorption associated with multiple myeloma (5) , in osteoporosis associated with estrogen deficiency (33, 34) , and in the high turnover state of the skeleton in patients with Paget's disease (35) . As opposed to the effect ofIL-6 on osteoclasts, the effect ofthe cytokine on the function of the osteoblast is much less certain. Although produced by both rodent (23) and human osteoblastic cell systems (36) , IL-6 has been shown to affect growth and differentiation in rodent osteoblasts (23, 37, 38) without having any effect on human osteoblasts (36) .
In order to shed more light on the role ofIL-6 in the metabolism of the osteoblast, we decided to study the interaction of IL-6 with the major signaling pathways activated by calciotropic hormones in osteoblasts, namely, intracellular Ca2+ ([Ca21]i) and cAMP. It is now well established that the osteoblast plays a key role in both bone formation and bone resorption processes stimulated by osteotropic agents (39, 40) . Moreover, the Ca2' and cAMP messenger systems generated inside the osteoblastic cytosol mediate many of the effects of calciotropic hormones (41) (42) (43) (44) . Given the in vivo observation of cooperativity between IL-6 and calciotropic hormones on bone remodeling, it is conceivable that the cytokine impinges on transduction pathways generated by hormones.
For these studies, we used the clonal cell line UMR-106. These cells share many phenotypic features with normal osteoblasts (45) . In addition, UMR-106 cells produce (25) and also exhibit biological effects in response to the cytokine (37) . Because these are transformed osteoblastic cells, we verified the reproducibility of our results by repeating several key experiments in primary cultures from neonatal rat calvariae.
Methods
Dr. T. J. Hahn (Veterans Affairs Medical Center, West Los Angeles, CA), who in turn generously supplied us with these cells. Cells were used between passages 10 and 12 and subpassages 3 and 14. Cells were seeded at a density of 2.5 X 10' cells/cm2 in tissue culture flasks or multiwell plates and grown at 370C in a humidified 95% air-5% CO2 atmosphere in Ham's F12-Dulbecco's modified Eagle's media (1:1) supplemented with 14.3 mM NaHCO3, 1.2 mM L-glutamine, 7% fetal bovine serum, 0.1 mg/ml streptomycin, and 100 U/ml penicillin. The cells reached confluence within 6-7 d in culture and were used on days 6-8 of growth.
Primary osteoblast culture was prepared from calvariae of 1-2 dayold Sprague-Dawley rats by using a successive enzymatic digestion method (46). Briefly, calvariae were removed and cleaned from the adherent tissue under a dissecting microscope. The bone tissue was cut into small pieces and digested with a mixture of trypsin/collagenase and bacterial collagenase (2.0 mg/ml) for 20 min at 370C. The bone pieces were minced with divalent ion-free PBS then resuspended in trypsin/collagenase solution for 40 min and washed with PBS. After a second 40-min digestion, the pieces were vortexed and filtered through a metal mesh (Millipore Corp., Bedford, MA) and then through IO Data are expressed as total counts per minute of 6-ml eluates for each inositol phosphate metabolite per 106 cells. Determination of cellular cAMP levels. Determination of cellular cAMP levels was done in culture plates containing 24 multiwells per plate. Cells preincubated with IL-6 or vehicle (PBS + 0.1% albumin) were acutely (from 5 min to 2 h) stimulated with agonists dissolved in 1 ml of BSS solution at 370C in the presence of 0.2 mM 3-isobutyl-l-methylxanthine. The reaction was terminated by aspirating the medium containing the stimulant and then adding 0.5 ml Lpropanol to extract the cAMP from the cell layer. The cell layers were then kept at 4°C for 1 h. The propanol extract was removed to glass tubes, the propanol was evaporated under a stream ofnitrogen gas, and the dried extract was kept at -70°C until assay. Before assay, the extract was reconstituted with sodium acetate buffer, pH 6 Endothelin, the most potent vasoconstrictor agent, has also been shown to activate plasma membrane receptors in osteoblastic cells and to induce [Ca2+]i responses in these cells (52) .
The effect of IL-6 on Ca2+ transients induced by I0-' M ET-I in UMR-106 cells is described in Fig. 3 . Once again, the cytokine significantly blunts [Ca2+]i increments induced by ET-l either in the presence of (Fig. 3, A PTH, PGE2, and ET-l was not altered by indomethacin (data not shown), thus indicating that the effect of the cytokine was independent of PGE2 production.
IL-6 effect in the presence of TK inhibitors. IL-6 has been shown to activate intracellular TKs as its main signal transduction (21, 22) . We, therefore, tested the possibility that the suppressive effect of IL-6 on hormonal mediated Ca2+ signals is mediated through the activation of intracellular TK. Toward that end, we studied the effect of IL-6 on Ca2+ transients in vehicle (DMSO)-treated cells as compared to cells pretreated for 24 h with 50 ng/ml herbimycin A. This antibiotic drug has been shown to inhibit a number of intracellular TKs including the src TK, while having no effect on serine/threonine kinase, protein kinase A, and protein kinase C (53) . Fig. 4 (55) . Thus, changes in fura-2 fluorescence induced by Mn2+ can be used to estimate Ca2+ entry across the plasma membrane. In the experiment described in Fig. 6 , UMR-106 cells were exposed to Ca24 -free media (containing EGTA) with (Fig. 6, C and D) or without (Fig. 6, A Fig. 6, B and D) . The IL-6 effect on [Ca2+]i increments was the same regardless of the absence (Fig. 6, A (Fig. 7 A) . In cells treated for 24 h with 200 U/ml IL-6 ( Fig. 7 a) To study the effect of IL-6 on the properties ofthe depolarization-activated Ca2+ channel, we acutely exposed the cells to BaCl2 in Ca2+-free media (Fig. 7, B and b) . Barium blocks the exit of potassium from the cells, thereby causing membrane depolarization. Cell depolarization activates a voltage-gated channel through which barium (in this case, replacing Ca2+) can enter the cell. The entry ofbarium is detected by its binding to fura-2, which elicits a fluorescent signal. Because accurate calculation of the Kd of fura-2 to barium is fraught with great difficulty, it was impossible to calibrate the barium signal. It is, however, clear that, on a qualitative basis, barium entered the cells at a rate and extent that were similar in both control (Fig.  7 B) and IL-6-treated cells (Fig. 7 b) .
The data presented in Figs. 6 400 U/ml (-90% suppression after 24 h of preincubation). 200 U/ml IL-6, which is the dose most commonly used in our studies, produced 60 (23, 25) . It is, therefore, conceivable that the IL-6 effect described here bears a physiological significance.
Time course for IL-6 effect. As shown in Fig. 9 , the first significant inhibition of PGE2 induced Ca 2+ transient was observed after 8 h of preincubation with 200 U/ml IL-6 (19±2% inhibition; P < 0.05 vs. control). The maximum inhibitory effect of IL-6 was observed after 48 h of preincubation (65±4% inhibition; P < 0.01 vs. control).
Effect ofIL-6 on PTH dose responsefor [ Ca2 ]i rise. Fig. 10 describes the effect ofpreincubation with 200 U/ml IL- 6 Effect of IL-6 on PGE2-stimulated 1.4.5-IP3 production.
Since the release of Ca2+ from intracellular stores is closely linked to the inositol phosphate turnover, we next measured the effect of IL-6 on phosphatidylinositol metabolism. Fig. 11 describes the effect of IL-6 on the production of IP,, IP2, and IP3 mediated by PGE2 in UMR-106 cells. We used PGE2 as an agonist in this study since we have shown that in UMR-106 cells, PGE2 is a potent stimulator of IP3 generation (44) . In preliminary experiments, we found a significant increase in IP3 after 10 s of stimulation with PGE2. After 30 s of stimulation, IPI was elevated whereas IP3 was undetectable. This finding is probably related to the fact that 30 s is a long enough time during which 1P3 is already degraded to IP2 and IP1. Based on these findings, we measured phosphoinositol production after 10-s stimulation with PGE2. As shown in Fig. 11 IL-6 effect on agonist-induced cAMP production. Since cAMP serves as another second messenger, alongside [Ca2+]i, mediating the effects ofcalciotropic hormones in bone, we studied the effect of IL-6 on agonist-mediated cAMP production.
We measured cAMP production in response to PTH, PGE2, forskolin and cholera toxin. Forskolin and cholera toxin were used, respectively to activate the catalytic and stimulatory (Gj) subunit of adenylyl cyclase independent of hormonal binding to a receptor. The data presented in Table I demonstrate that IL-6 did not influence cAMP production by either receptor (PTH and PGE2) or nonreceptor (forskolin and cholera toxin) mechanisms.
Effect ofIL-6 on cell growth. We have recently shown that various osteotropic factors (e.g., PTH, PGE2) mediate their effects on osteoblast function through the Ca2' and cAMP signaling systems (44, 56) . Among the pleiotropic effects mediated by these messenger systems, cAMP is antiproliferative in osteoblasts whereas the Ca2+ signaling system, while not having an effect on proliferation by itself, antagonizes the antiproliferative effect of cAMP (44, 56 Figure 7 . IL-6 effect on PKC-and depolarization-activated Ca2" entry pathways. UMR-106 cells were cultured for 24 h in serum-free DME containing either vehicle alone (A and B) or 200 U/ml IL-6 (a and b). On the day of the experiment, cells were loaded with fura-2 as described in Methods. In A and a, cells were perfused with BSS containing 1.5 mM CaC12. PMA (1 MM) was added as indicated and fluorescence was recorded. In B and b, cells were bathed in Ca2+-free BSS. After stabilization ofthe signal, mM BaCl2 was added as indicated. This experiment represents one of five similar experiments.
since IL-6 attenuates [Ca2+]i rise by calciotropic hormones, it may impinge on the effects of hormones on cell proliferation. Fig. 12 demonstrates that in UMR-106 cells, PGE2 dose dependently inhibits [3H]thymidine uptake. Pretreatment for 24 h with 200 U/ml IL-6 by itself did not have an effect on cell proliferation. However, when combined with PGE2, there was a marked potentiation of the antiproliferative effect of PGE2.
We compared the effect of IL-6 to that of the phorbol ester, PMA. We (44) have shown that similarly to IL-6 phorbol esters also attenuate hormonally mediated increase in [Ca2+]i in osteoblasts without affecting cAMP production. As shown in Fig.  12 , 10 nM PMA, while having no effect of its own on cell proliferation, greatly enhanced the antiproliferative effect of PGE2, an effect similar to that of IL-6. The combination of IL-6 and PMA did not result in additional enhancement of PGE2 induced antiproliferation beyond that produced by each agonist alone (not shown).
The experiment described in Fig. 12 was repeated in calvarial osteoblasts. The results were qualitatively comparable to those obtained in UMR-106 cells. PGE2 at doses of 1 and 10
MiM inhibited [3H]thymidine uptake by 54% and 76%, respectively (control 100%). Pretreatment of the cells for 24 h with 200 U/ml IL-6 had no effect on cell proliferation but when combined with PGE2, the cytokine enhanced the antiproliferative effect of PGE2 (reduction by 75% and 92% from control at 1 and 10 MuM PGE2, respectively; P < 0.01 PGE2 alone vs. PGE2 + IL-6). Table II It is currently known that the biological effects of IL-6 in target organs are mediated by a specific membrane receptor (IL-6R) which belongs to cytokine receptor superfamily based on structural and functional similarities (16) (17) (18) (19) (20) (21) (22) . Since the main signal transduction activated by the association of IL-6 with its receptor involves tyrosine phosphorylation of intracellular proteins (20) (21) (22) , we tested the effect of TK inhibitors on the IL-6 effects as demonstrated in our study. Our data show that herbimycin A, a highly specific inhibitor of intracellular TKs (53) abolished the inhibitory effect ofIL-6 on hormonally induced Ca2" transients. This effect was not shared by another TK inhibitor, tyrphostin (RG50863) which is more specific for receptor TKs (e.g., EGF receptor). Since the two TK inhibitors also differ in their ability to inhibit TK activity encoded by the c-src gene (53, 57) , our data provide an indirect evidence for possible role of src TK in mediating some of IL-6 effects in osteoblasts. However, in the absence of more direct assays of src activity, the possibility ofother intracellular TKs mediating 160-140-0 = 120-11 10 9 -LOG [PTHJ osteoblasts. Others and we have shown that the pleiotropic functions of these hormones on bone metabolism can be explained on the basis of antagonistic effects between the Ca2+ and cAMP signaling pathways (41) (42) (43) (44) 56) . With respect to cell growth, the cAMP messenger system is antiproliferative, while
[Ca2+]j, although having no effect of its own on cell growth, antagonizes the cAMP antiproliferative effect (44, 56 (44) . The enhancing influence of IL-6 on the antimitotic effect of hormones could not be ascribed to increased cAMP levels since IL-6 does not modify cAMP production in osteoblasts (Table I) . Our study adds to the overall gamut of IL-6 effects on bone metabolism. The majority of evidence currently available suggests that IL-6 stimulates bone resorption by enhancing osteoclast recruitment from hematopoietic precursors (23, 25, 28, 29) . However, the data regarding IL-6 effect on the osteoblast have, thus far, yielded conflicting results. While some investigators have shown modest effect ofthe cytokine on cell proliferation (37) and differentiation (23) , others have failed to demonstrate IL-6 effect on proliferation, alkaline phosphatase activity, or osteocalcin production in osteoblastic cells (36) . However, even in cells in which IL-6 has been shown to exert no effect (such as human osteoblastic cells and ROS 17/2.8 cells [ 36 ] ), the cells produce IL-6 and also express mRNA for the IL-6 receptor (36) . Based on our data, we suggest that IL-6 has a paracrine/autocrine role, whereby after its secretion from the osteoblast in response to calciotropic hormones, IL-6 feeds back on the osteoblast to modulate signaling pathways generated by the hormones. This, in turn, will affect osteoblastic function (e.g., cell proliferation). In addition, IL-6 acts on hematopoietic progenitors to recruit osteoclasts thereby stimulating bone resorption.
